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Introduction: The first-line treatment for acromegaly is transsphenoidal surgery. In approximately 50% of patients,
however, a cure is not possible with surgery and alternatives are needed. Somatostatin analog therapy is the
recommended first-line treatment in patients with such cases. Here we provide the first report of a high-dose
lanreotide primary therapy in patients with acromegaly.
Case presentation: Six patients who were not suitable for surgery were given 60 mg of lanreotide (Autogel®)
every four weeks. All patients were German nationals and Caucasian.
When the response of our patients was unsatisfactory, the dose was increased sequentially to 90 mg every four
weeks, 120 mg every four weeks, 120 mg every three weeks and 180 mg every three weeks. Treatment duration
was 12 to 24 months. In all cases, the lanreotide dose was 120 mg every 4 weeks or higher. In five of our patients,
growth hormone (GH) levels were successfully reduced (in three patients GH <2.5 ng/ml was achieved). Insulin-like
growth factor 1 levels were normalized in three patients and decreased in two patients. One patient failed to show
a biochemical response to lanreotide therapy or pegvisomant therapy.
Tumor shrinkage or degeneration was observed in the five responding patients. No drug-related adverse events
were noted.
Conclusions: These results suggest that lanreotide at high doses of 120 mg every four weeks or more is an
effective first-line therapy for patients with acromegaly that surgery alone cannot treat.
Introduction
Acromegaly, characterized by elevated growth hormone
(GH) and insulin-like growth factor 1 (IGF-1) levels, is
associated with a range of cardiovascular, respiratory,
endocrine, metabolic and compression symptoms, and
with an increased cancer risk [1-3]. Some symptoms can
be serious and life-threatening. If untreated, acromegaly
reduces life expectancy [4,5].
Transsphenoidal surgery is the first-line treatment for
acromegaly. However, surgery may be impractical. In
approximately 50% of patients, surgery alone is unlikely
to control the disease. In cases where there is a low
probability of surgical cure, primary treatment with a
long-acting somatostatin analog is recommended [6,7].
Two somatostatin analogs are available, such as octreo-
tide (Sandostatin®, Novartis) and lanreotide (Autogel®,
Ipsen). There are considerable clinical data on the first-
line use of octreotide (for example, Colao et al. [8]).
Lanreotide, on the other hand, has been shown to be
effective as secondary treatment at starting doses of 30
mg to 120 mg every four weeks [9], but only recently
have data been published on the use of lanreotide 90 mg
or 120 mg every four weeks as primary therapy [10].
We present six patients with acromegaly who received
primary treatment with lanreotide at doses higher than
those presented in the literature.
GH, IGF-1 and prolactin levels were measured using
chemiluminescent immunometric assays with Immulite
2000 (Siemens Medical Solutions Diagnostics, formerly
DPC, Los Angeles, USA). Normal GH levels were
defined as 0.5 to 5.0 ng/ml and normal age-adjusted
IGF-1 levels were between 81 and 483 ng/ml.
Magnetic resonance tomography was conducted with
a 1.5 Tesla-System (Siemens, Erlangen) Type AVANTO,
and 1.5 T. MR (Avanto, Siemens). Magnetic resonance
imaging (MRI) images were produced using a head
matrix array. For pituitary imaging, T2w-TSE sag, T1w-
SE sag and coronar before and after contrast medium * Correspondence: wuester@endokrinologie-mainz.de
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dynamically. The slice size was 2.2 mm.
The six patients with acromegaly presented in this case
series were ineligible for surgery because three of them
had macroadenoma that were too large and had parasel-
lar and suprasellar extensions (Patients 1, 5 and 6), while
one had an adenoma that was too close to the internal
carotid artery (Patient 2). One had cardiac insufficiency
stage New York Heart Association (NYHA) III and severe
insulin-dependent diabetes mellitus and was thus consid-
ered high risk for systemic anesthesia (Patient 3), while
one had McCune-Albright syndrome and fibrous dyspla-
sia involving the base of the skull which made transsphe-
noidal surgery impossible (Patient 4).
All patients were German nationals and Caucasian.
All patients initially received lanreotide by deep subcu-
taneous injection (Autogel®, Ipsen, Paris, France). Each
patient was given a single starting dose of 60 mg. After
four weeks, their IGF-1 and GH levels were measured. If
the IGF-1 levels remained high and the response of our
patient to the medication was unsatisfactory, the next
dose of lanreotide was increased to 90 mg or 120 mg. If a
patient who was receiving treatment with 120 mg, had an
unsatisfactory IGF-1 response, the injection interval was
reduced to every three weeks. If GH and IGF-1 levels
were still elevated in patients receiving lanreotide 120 mg
every three weeks, the dose was increased to 180 mg, or
90 mg in each gluteal muscle, every three weeks. For
each patient, the dose adjustments were usually made
after three injections of lanreotide. In single cases with
very high IGF-1-levels, the decision to increase the dose
was made earlier based on our previous experience with
this treatment.
Case report 1
A 19-year-old Caucasian woman of German nationality
presented to our hospital in October 2006 with persis-
tent visual disorders. A large pituitary tumor was diag-
n o s e db yM R I ,b u tw a sd e e m e du n s u i t a b l ef o rs u r g i c a l
resection due to its parasellar and suprasellar extension.
Acromegaly was confirmed by standard endocrinologi-
cal examinations. Her GH level was >40 ng/ml and was
not suppressed by a standard oral glucose load. Her
IGF-1 levels were 631 ng/ml. However, the only clinical
sign of acromegaly was hyperhidrosis and there was no
evidence of hypopituitarism.
Our patient did not respond to the initial dose of lan-
reotide 60 mg, so the dose was increased to 120 mg
every four weeks. Her IGF-1 levels decreased to within
the normal range one month after this increase in
dosage. She remained relatively stable for 17 months.
After 10 months, the dose of lanreotide was increased
to 180 mg every three weeks (Figure 1 and Table 1).
Hyperhidrosis improved after the normalization of her
IGF-1 levels. Her GH levels were substantially reduced
after initiating the treatment, but they did not drop to
the target of <2.5 ng/ml at any time during the 17
months of treatment (Table 1).
The size of her tumor was reduced by approximately
50% (from 4.5 × 4.0 cm to 2.4 × 1.9 cm), 10 months
after initiating treatment (Figure 2), but was still not
completely resectable by surgery and so no surgical
intervention was attempted. Lanreotide treatment
continued.
Liver enzyme activities of our patient remained nor-
mal throughout, but liver ultrasonography was not per-
formed. Our patient tolerated the treatment well, and
she had no complaints of gastrointestinal discomfort.
Case report 2
A 52-year-old Caucasian woman of German nationality
presented to our hospital in January 2007. She was diag-
nosed with acromegaly when an MRI scan showed a
large pituitary tumor that was not suitable for surgical
removal because it was too close to the internal carotid
artery. Our patient had previously received surgery for
bilateral carpal tunnel syndrome and for goitre, had
sleep apnoea syndrome, and was experiencing essential
tremor. In addition, our patient suffered from a typical
enlargement of the nose, ears and lips. Her skin was
seborrhoic and she complained of acne. She had depres-
sion and was receiving antidepressants.
Her GH levels were 12 ng/ml and were not sup-
pressed by a standard oral glucose load. Her IGF-1
levels were 676 ng/ml. No evidence of hypopituitarism
could be found on our patient.
She was given a treatment with lanreotide 60 mg every
four weeks and her IGF-1 levels decreased (Table 1).
After eight months, however, her IGF-1 levels were still
above the upper limit of normal (ULN), and the dose of
lanreotide was increased to 120 mg every four weeks.
Increases in her IGF-1 levels at 12 months led to a
further dose increase to 180 mg every three weeks. In
April 2008, (approximately 14 months after initiating
treatment), her IGF-1 and GH levels had decreased to
within, or close to, the normal range (Table 1), which
was at 332 ng/ml for IGF-1 and <2.5 ng/ml for GH.
On publication, MRI images show tumor degeneration
with cystic decay within the tumor, and lanreotide treat-
ment continues at 180 mg every four weeks.
Liver enzyme activities of this patient remained nor-
mal throughout, but liver ultrasonography was not per-
formed. She tolerated the treatment well and reported
no gastrointestinal discomfort.
Case report 3
A 63-year-old Caucasian woman of German nationality
and with a 40-year history of type 1 diabetes and poor
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Page 2 of 6Figure 1 Insulin-like growth factor 1 values in Case 1 during lanreotide treatment for one year. Baseline value is pre-treatment value.
Lanreotide dose increased from 60 mg to 120 mg every four weeks after one month and to 180 mg every three weeks after 10 months. Upper
limit of normal is 483 ng/ml.
Table 1 Growth hormone levels and IGF-1 levels after initiating primary lanreotide treatment in six patients with
acromegaly























1 GH >40 6.5 17.2 5.5-12.3 7.3-10.1 9.2 6.6
IGF-1 631 378-381 318-488 205-601 390-392 289 317
2 GH 12 5.6 1.6 1.3-1.8 1.8 1.0-1.2
IGF-1 676 482-566 280-345 293-427 411 332
3 GH 3.9 1.8 2.0 2.5 2.8 2.6 3.1 4.3 4.6 3.6
IGF-1 621 582 599 630 763-770 695 514 442 565 725
4 GH 5.8** 5.8 3.9 3.6
IGF-1 351** 414 395 320
5 GH 0.6 0.4-0.8 0.5 0.3
IGF-1 338 272-301 239-285 212
6 GH 4.2 1.2-1.6 1.6 1.3 1.3
IGF-1 413 285-414 267 286 395 267 260 260
*Patients assessed at different time-points within the range
**Before treatment with lanreotide but after treatment with octreotide for approximately 13 and 27 months for the GH and IGF-1 values, respectively.
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hospital with a pituitary tumor in April 2006. She had
elevated IGF-1 levels of 621 ng/ml, and high to normal
GH levels of 3.93 ng/ml. There was no evidence of
hypopituitarism. Although she had no overt symptoms
of acromegaly, her cardiac function was improved when
her GH and IGF-1 levels were reduced as she had less
dyspnoea. The management of her diabetes was also
more effective (with fewer episodes of severe hypogly-
caemia) when her GH and IGF-1 levels were controlled.
In June 2006, she was started on lanreotide 60 mg
every four weeks. There was no significant reduction in
her IGF-1 levels and the dose of lanreotide was then
increased to 120 mg every four weeks. After 11 months
of treatment with lanreotide, her IGF-1 and GH levels
were largely unchanged from their levels before the
treatment (Table 1).
Since she appeared to be insensitive to somatostatin
analog treatment and did not consent to a dose increase,
the dose was not increased any further. Instead, she was
initiated on the GH antagonist pegvisomant (Somavert®,
Pfizer, UK) at a dosage of 120 mg/day and her lanreotide
treatment was stopped. After a further 12 months of this
treatment, her GH levels remained high to normal, and
her IGF-1 levels remained well above the ULN (Table 1).
No tumor shrinkage was seen in any of her MRI
scans.
Case report 4
Diagnosed with acromegaly and with a suspicion of
fibrous dysplasia in November 2004, a 61-year-old
Caucasian man of German nationality was noted to
have McCune-Albright syndrome (with a G®Am u t a -
tion in exon 8, codon 201 of the GNAS-1 gene) and
clinical symptoms that included café au lait marks.
His IGF-1 values were 616 ng/ml (ULN was 212 ng/
ml for age-matched controls) at the time of diagnosis,
and his GH levels were 8.48 ng/ml and not suppressed
by a standard oral glucose load.
Our patient was initially treated with 10 mg of octreo-
tide every four weeks for 27 months. During this time
his IGF-1 levels ranged from 329 to 509 ng/ml, and his
GH levels ranged from 4.54 to 7.69 ng/ml. Disease con-
trol with octreotide was therefore inadequate and our
patient was switched to 120 mg of lanreotide every four
weeks. After 10 months of treatment with lanreotide,
his IGF-1 levels were 320 ng/ml and GH levels were
3.6 ng/ml (Table 1), indicating some improvement in
his status. MRI scans showed a tumor size reduction
from 8 × 5 mm to 6 × 3 mm.
Case report 5
In April 2004, a 45-year-old Caucasian man of German
nationality presented with a pituitary tumor that mea-
sured 3.4 × 3.8 × 3.8 cm, prolactin levels of 530 ng/ml
(ULN: 20 ng/ml) and IGF-1 levels of 315 ng/ml (ULN
was 212 ng/ml for age-matched controls).
A dopamine agonist, cabergoline 1 mg, was adminis-
tered to our patient three times per week. The prolactin
and IGF-1 levels of our patient was thus normalized
(IGF-1 was 188 ng/ml) within four weeks. After one year,
an MRI assessment showed that the diameter of the
Figure 2 (A) Magnetic resonance imaging scan showing the tumor size before lanreotide treatment. (B) Magnetic resonance imaging
scan showing a reduction in tumor size after 10 months of lanreotide treatment in Case 1.
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By January 2007, and with a continuation of cabergoline
doses that suppressed prolactin increases, the IGF-1
levels of our patient had increased to 338 ng/ml. Basal
GH levels were 0.56 ng/ml. Therefore, our patient was
initiated on a treatment with lanreotide 60 mg every four
weeks. Despite reductions in IGF-1 levels to as low as
239 ng/ml after seven months, the lanreotide dose was
increased initially to 90 mg every four weeks, and then to
120 mg every four weeks one month later. After 10
months of treatment with lanreotide, our patient’sI G F - 1
levels had normalized to 212 ng/ml. GH levels remained
well below 2.5 ng/ml during the lanreotide therapy.
Tumor size was reduced to 2.4 × 2.8 × 3.3 cm.
Case report 6
A 53-year-old Caucasian man of German nationality
presented to our hospital in February 2004 with a pitui-
tary tumor measuring 3.1 × 3.6 cm. Our patient had ele-
vated prolactin values (2940 ng/ml) but normal GH
values (0.27 ng/ml) and IGF-1 values (127 ng/ml).
He was initiated on a 1 mg cabergoline treatment three
times per week. But it had to be increased after three
months to 1 mg/day to normalize his prolactin levels. His
IGF-1 levels subsequently increased; reaching 312 ng/ml
eight months after presentation and 413 ng/ml 25
months after presentation (ULN was 267 ng/ml for age-
matched controls). Similarly, his GH levels increased
over time to basal levels of 4.23 ng/ml after 22 months,
and were not suppressed by standard oral glucose load.
However, 12 months after presentation, the tumor mass
had reduced to 2 cm in diameter. In March 2006, he was
started on treatment with lanreotide 60 mg every four
weeks, and four months later his IGF-1 levels normalized
to 285 ng/ml and GH levels was reduced to <2.5 ng/ml
(Table 1). Subsequent dose increases of lanreotide to
90 mg every four weeks and then to 120 mg every four
weeks maintained his IGF-1 and GH at normal levels. As
of publication, the most recent MRI finding shows signs
of tumor regression. Cabergoline treatment was contin-
ued and unchanged during this time.
No adverse events related to lanreotide treatment were
recorded in any of the six patients we described.
Conclusions
This series of six patients with acromegaly is one of the
first specific reports of primary treatment with lanreo-
tide, and the first to report the use of high doses. The
six patients were not eligible for surgical removal of
their pituitary tumors, and five patients showed a bio-
chemical response to lanreotide treatment, which was
given for one to two years. The response of our patients
to lanreotide treatment occurred within one to two
months, but required dose increases to 120 mg every
four weeks, while two patients subsequently required
180 mg every three weeks to achieve or maintain their
initial response. Furthermore, the five patients that
responded also had evidence of tumor shrinkage or
degeneration while receiving lanreotide.
The goals of treatment for acromegaly are to reduce
GH levels to <2.5 ng/ml, normalize IGF-1 levels, and/or
control tumor mass [6,7]. Based on these goals, lanreo-
tide was proven to be a successful first-line therapy in
five of these six patients, with the exception of Case 3,
as this patient did not respond to high-dose lanreotide
or to pegvisomant.
The other unique aspect of this case series is the high
dose of lanreotide (180 mg every three weeks) that was
given to two of our patients. This high dose of lanreo-
tide has now been given to one patient for approxi-
mately six months and to another for approximately
three months with no unexpected adverse events. The
use of such high doses of lanreotide has not been pre-
viously published, and our experience suggests that this
dose is well-tolerated, at least in the short-term, and
may be useful for patients showing an attenuation of
response to lanreotide doses of 120 mg every four
weeks.
This report confirms the efficacy and tolerability of
lanreotide in the primary treatment of acromegaly.
Further data are required regarding the use of lanreotide
in this setting, as well as to identify the potential clinical
risks and benefits of high-dose lanreotide.
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